Showing results (181-190 of 302) with videos related to

Sort By:
Pageof 31
Orphanet Journal of Rare Diseases|March 3, 2021
B cell-activating factors in autoimmune pulmonary alveolar proteinosisMasaki Hirose, Toru Arai, Chikatoshi Sugimoto, et al.
Respiratory Investigation|November 21, 2025
Psychological palliative care for patients with interstitial lung disease in Japan: A secondary analysis of a National Survey of Japanese Respiratory PhysiciansYoshinobu Matsuda, Tomoyuki Fujisawa, Tatsuya Morita, et al.
Palliative Medicine Reports|July 5, 2021
Predictors of Morphine Efficacy for Dyspnea in Inpatients with Chronic Obstructive Pulmonary Disease: A Secondary Analysis of JORTC-PAL 07Yoshinobu Matsuda, Tatsuya Morita, Hirotaka Matsumoto, et al.
Japanese Journal of Radiology|October 9, 2025
Volume histogram analysis of whole-lung CT: differentiating usual from nonspecific interstitial pneumonias and predicting prognosisTomonori Chikasue, Hiromitsu Sumikawa, Akiko Sumi, et al.
Respirology (Carlton, Vic.)|March 6, 2019
Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumoniasToru Arai, Hiroshi Kida, Yoshitaka Ogata, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|November 14, 2019
Change in lung function in never-smokers with nontuberculous mycobacterial lung disease: A retrospective studyTakehiko Kobayashi, Kazunari Tsuyuguchi, Toru Arai, et al.
Respiratory Investigation|November 30, 2024
Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosisToru Arai, Yoshikazu Inoue, Keiichi Akasaka, et al.
Respiratory Medicine|May 20, 2014
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosisLuca Richeldi, Vincent Cottin, Kevin R Flaherty, et al.
Msphere|July 7, 2021
Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in JapanFuminori Mizukoshi, Nobuyuki Kobayashi, Fumiko Kirikae, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical TrialRyo Okuda, Yasuhiko Nishioka, Yasuhiro Kondoh, et al.
Pageof 31